MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’
An MoU for the production of Goat Pox Vaccine and “Lumpi-Provac” vaccine was signed in Nagpur on December 29, 2022 in the presence of Union Minister of Fisheries, Animal Husbandry, Parshottam Rupala and Chief Minister of Maharashtra Eknath Shinde.
Rupala praised the commendable effort put forth by ICAR in developing indigenous vaccine Lumpi-ProVac for LSD.
Lumpi-ProVaccine is used for the prophylactic immunization of animals against Lumpy Skin Disease.
The vaccine technology will meet the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease.
Goat pox vaccine is currently used to control lumpy Skin Disease in livestock and has been shown to be effective against lumpy.
Union Minister Rupala further highlighted the relevance of the technology and requested the IVBP, Pune to start manufacturing the vaccine at a large scale without any delay.
National Centre for Veterinary Type Culture, ICAR-National Research Centre on Equines (ICAR-NRCE), Hisar (Haryana), in collaboration with ICAR-Indian Veterinary Research Institute (IVRI), Izatnagar (UP) developed a homologous live-attenuated LSD vaccine, named Lumpi-ProVacInd.
Agrinnovate India Limited (AgIn), the commercial arm of DARE, Ministry of Agriculture and Farmers’ Welfare, granted “Non-Exclusive Rights” for Commercial production of “Lumpi-ProVac”, to Institute of Veterinary Biological Products (IVBP) , Pune.
Lumpy Skin Disease
It is caused by infection of cattle or buffalo with the poxvirus Lumpy skin disease virus (LSDV).
The virus is one of three closely related species of the genus Capripoxavirus.
The other two species are Sheeppox virus and Goatpox virus.
Due to its infectious nature and its impact on the economy, the World Organization for Animal Health (WOIE) has declared it a notable disease.
Please Rate this article, so that we can improve the quality for you -